Loading stock data…
ACAD
$21.95-0.50 (-2.23%)
Market ClosedLast close May 1
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ACADIA Pharmaceuticals Inc. in the Healthcare sector is trading at $21.95. The stock is currently 23% below its 52-week high of $28.35, remaining 7.6% below its 200-day moving average. Technical signals show neutral RSI of 55 and bullish MACD crossover, explaining why ACAD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 55) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$21.95
Potential Upside
124.9%
Whystock Fair Value$49.37
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus20 analysts
Buy
Mean target$31.70+44.4%
Range$17.00 – $45.00
Fundamentals
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agon...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.77B
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
9.61
Beta
Defensive asset. Lower volatility than the S&P 500.
0.83
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
18.10%
Volume
Today's trading volume
1.10M
Recent News
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
CSLLY vs. ACAD: Which Stock Is the Better Value Option?
Iovance Biotherapeutics (IOVA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acadia Pharmaceuticals (ACAD) Expected to Beat Earnings Estimates: Should You Buy?
Acadia (ACAD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ACADIA Pharmaceuticals Inc. (ACAD) PT Trimmed Slightly as RBC Flags Seasonal Biotech Headwinds
We recently compiled a list of the 9 Most Undervalued Healthcare Stocks to Buy Now. ACADIA Pharmaceuticals Inc. is one of the most undervalued healthcare stocks to buy now. TheFly reported on April 7 that RBC Capital Markets revised its outlook on ACAD, lowering its price target from $30 to $29 while keeping an Outperform […]
How Investors Are Reacting To ACADIA Pharmaceuticals (ACAD) Expanding DAYBUE STIX Access for Rett Syndrome
Acadia Pharmaceuticals has now made DAYBUE STIX, a dye- and preservative-free powder formulation of trofinetide for oral solution, broadly available in the US for treating Rett syndrome in adults and children aged two and older, following FDA approval in December 2025. The new packet-based, bioequivalent formulation, which can be mixed with various water-based drinks, offers patients and caregivers added flexibility and convenience while expert consensus papers increasingly reference...